T-Cure Bioscience, Inc. and Atlas Antibodies AB Enter a Collaboration Agreement for the Development, Manufacture, and Supply of CT83 (KK-LC-1) Monoclonal Antibodies

LOS ANGELES--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the development, manufacture, and...

Click to view original post